Changes in Hong Kong stocks | Pegasus Medical-B (09996) is now up more than 3%, and the chairman is about to make significant progress in increasing his shares in the open market in various products

The Zhitong Finance App learned that Peijia Medical-B (09996) is now up more than 3%. As of press release, it has risen 2.6% to HK$5.92, with a turnover of HK$8.934,900.

According to the news, on December 5, Peijia Healthcare announced that Dr. Zhang Yi, the company's executive director, CEO and chairman of the board of directors, began purchasing the company's shares on the open market on December 1, 2025. The total cost of increased shareholding is expected to be no more than HK$15 million. According to the announcement, Dr. Zhang Yi will not rule out the possibility of further increasing its shareholding in the company in due course in accordance with applicable laws and regulations.

CITIC Construction Investment released a research report stating that the company's TAVR products continue to be released, and the market share is steadily increasing; the GeminioneTeer system, Taurustrio aortic reflux valve, and TaurusNXT dry valve TAVR are expected to be intensively approved from the end of 2025 to 2026, driving the accelerated growth of the valve business; the MonarQ tricuspid valve system has launched a global clinical trial, and the cutting-edge technology business has received external financing, and the path to innovation is clear.